Phosphodiesterase 10 inhibition reduces striatal excitotoxicity in the quinolinic acid model of Huntington's disease

Neurobiology of Disease

Volumn 34, Issue 3, 2009, Pages 450-456

  Giampà, Carmela ^a   Patassini, Stefano ^a   Borreca, Antonella ^a   Laurenti, Daunia ^a   Marullo, Fabrizia ^a   Bernardi, Giorgio ^a,c   Menniti, Frank S ^b   Fusco, Francesca R ^a  

^a IRCCS FONDAZIONE SANTA LUCIA   (Italy)

^b PFIZER INC   (United States)

^c UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

Huntington's disease; Immunohistochemistry; PDE inhibitors; Rat; Striatum

Indexed keywords

CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; DRUG VEHICLE; PHOSPHODIESTERASE 10 INHIBITOR; PHOSPHODIESTERASE INHIBITOR; PHOSPHODIESTERASE INHIBITOR TP10; QUINOLINIC ACID; TP 10; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN DAMAGE; BRAIN SIZE; CELL SURVIVAL; CONTROLLED STUDY; CORPUS STRIATUM; EXCITOTOXICITY; HUNTINGTON CHOREA; MALE; NERVE DEGENERATION; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; RAT;

ANIMALS; BRAIN-DERIVED NEUROTROPHIC FACTOR; CELL SURVIVAL; CEREBRAL CORTEX; CORPUS STRIATUM; CYCLIC AMP RESPONSE ELEMENT-BINDING PROTEIN; DISEASE MODELS, ANIMAL; ENZYME INHIBITORS; HUNTINGTON DISEASE; MALE; NEURONS; NEUROPROTECTIVE AGENTS; PHOSPHORIC DIESTER HYDROLASES; PHOSPHORYLATION; QUINOLINIC ACID; RATS; RATS, WISTAR; RECEPTORS, COMPLEMENT;

EID: 67349165136     PISSN: 09699961     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nbd.2009.02.014     Document Type: Article

References (52)

1. Albin R.L., and Tagle D.A. Genetics and molecular biology of Huntington's disease. Trends Neurosci. 18 1 (1995) 11-14 (Jan)
2. Albin R.L., Young A.B., Penney J.B., Handelin B., Balfour R., et al. Abnormalities of striatal projection neurons and N-methyl-d-aspartate receptors in presymptomatic Huntington's disease. N. Engl. J. Med. 322 (1990) 1293-1298
3. Albin R.L., Reiner A., Anderson K.D., Dure L.S.t., Handelin B., et al. Preferential loss of striato-external pallidal projection neurons in presymptomatic Huntington's disease. Ann. Neurol. 31 (1992) 425-430
4. Augood S.J., Faull R.L., Love D.R., and Emson P.C. Reduction in enkephalin and substance P messenger RNA in the striatum of early grade Huntington's disease, a detailed cellular in situ hybridization study. Neuroscience 72 (1996) 1023-1036
5. Block F., Schmidt W., Nolden-Koch M., and Schwarz M. Rolipram reduces excitotoxic neuronal damage. Neuroreport. 12 7 (2001) 1507-1511 (May 25)
6. Conti M., and Beavo J. Biochemistry and physiology of cyclic nucleotide phosphodiesterases, essential components in cyclic nucleotide signaling. Annu. Rev. Biochem. 76 (2007) 481-511
7. Coskran T.M., Morton D., Menniti F.S., Adamowicz W.O., Kleiman R.J., et al. Immunohistochemical localization of phosphodiesterase 10A in multiple mammalian species. J. Histochem. Cytochem. 54 (2006) 1205-1213
8. DeMarch Z., Giampa C., Patassini S., Martorana A., Bernardi G., et al. Beneficial effects of rolipram in a quinolinic acid model of striatal excitotoxicity. Neurobiol. Dis. 25 (2007) 266-273
9. DeMarch Z., Giampa C., Patassini S., Bernardi G., and Fusco F.R. Beneficial effects of rolipram in the R6/2 mouse model of Huntington's disease. Neurobiol. Dis. 30 (2008) 375-387
10. Ferrante R.J., Kowall N.W., Richardson Jr. E.P., Bird E.D., and Martin J.B. Topography of enkephalin, substance P and acetylcholinesterase staining in Huntington's disease striatum. Neurosci. Lett. 71 (1986) 283-288
11. Ferrer I., Goutan E., Marín C., Rey M.J., and Ribalta T. Brain-derived neurotrophic factor in Huntington disease. Brain Res. 866 1-2 (2000) 257-261 (Jun 2)
12. Fusco F.R., Chen Q., Lamoreaux W.J., Figueredo-Cardenas G., Jiao Y., et al. Cellular localization of huntingtin in striatal and cortical neurons in rats, lack of correlation with neuronal vulnerability in Huntington's disease. J. Neurosci. 19 (1999) 1189-1202
13. Fusco F.R., Zuccato C., Tartari M., Martorana A., De March Z., et al. Co-localization of brain-derived neurotrophic factor BDNF. and wild-type huntingtin in normal and quinolinic acid-lesioned rat brain. Eur. J. Neurosci. 18 (2003) 1093-1102
14. Giampa C., DeMarch Z., D'Angelo V., Morello M., Martorana A., et al. Striatal modulation of cAMP-response-element-binding protein CREB. after excitotoxic lesions, implications with neuronal vulnerability in Huntington's disease. Eur. J. Neurosci. 23 (2006) 11-20
15. Gines S., Seong I.S., Fossale E., Ivanova E., Trettel F., et al. Specific progressive cAMP reduction implicates energy deficit in presymptomatic Huntington's disease knock-in mice. Hum. Mol. Genet. 12 (2003) 497-508
16. Gutekunst C.A., Li S.H., Yi H., Mulroy J.S., Kuemmerle S., et al. Nuclear and neuropil aggregates in Huntington's disease, relationship to neuropathology. J. Neurosci. 19 (1999) 2522-2534
17. Hebb A.L., Robertson H.A., and Denovan-Wright E.M. Striatal phosphodiesterase mRNA and protein levels are reduced in Huntington's disease transgenic mice prior to the onset of motor symptoms. Neuroscience 123 (2004) 967-981
18. Hosoi R., Ishikawa M., Kobayashi K., Gee A., Yamaguchi M., et al. Effect of rolipram on muscarinic acetylcholine receptor binding in the intact mouse brain. J. Neural Transm. 110 (2003) 363-372
19. Houslay M.D., and Adams D.R. PDE4 cAMP phosphodiesterases, modular enzymes that orchestrate signalling cross-talk, desensitization and compartmentalization. Biochem. J. 370 (2003) 1-18
20. Hu H., McCaw E.A., Hebb A.L., Gomez G.T., and Denovan-Wright E.M. Mutant huntingtin affects the rate of transcription of striatum-specific isoforms of phosphodiesterase 10A. Eur. J. Neurosci. 20 12 (2004) 3351-3363
21. Jacob C., Szilagyi C., Allen J.M., Bertrand C., and Lagente V. Role of PDE4 in superoxide anion generation through p44/42MAPK regulation, a cAMP and a PKA-independent mechanism. Br. J. Pharmacol. 143 (2004) 257-268
22. Jiang H., Nucifora Jr. F.C., Ross C.A., and DeFranco D.B. Cell death triggered by polyglutamine-expanded huntingtin in a neuronal cell line is associated with degradation of CREB-binding protein. Hum. Mol. Genet. 12 (2003) 1-12
23. Kazantsev A., Preisinger E., Dranovsky A., Goldgaber D., and Housman D. Insoluble detergent-resistant aggregates form between pathological and nonpathological lengths of polyglutamine in mammalian cells. Proc. Natl. Acad. Sci. U. S. A. 96 (1999) 11404-11409
24. Lee H.T., Chang Y.C., Wang L.Y., Wang S.T., Huang C.C., et al. cAMP response element-binding protein activation in ligation preconditioning in neonatal brain. Ann. Neurol. 56 (2004) 611-623
25. Lee J., Kim C.H., Simon D.K., Aminova L.R., Andreyev A.Y., et al. Mitochondrial cyclic AMP response element-binding protein CREB. mediates mitochondrial gene expression and neuronal survival. J. Biol. Chem. 280 (2005) 40398-40401
26. Lonze B.E., and Ginty D.D. Function and regulation of CREB family transcription factors in the nervous system. Neuron. 35 4 (2002) 605-623 (Aug 15)
27. Luthi-Carter R., Strand A., Peters N.L., Solano S.M., Hollingsworth Z.R., et al. Decreased expression of striatal signaling genes in a mouse model of Huntington's disease. Hum. Mol. Genet. 9 (2000) 1259-1271
28. Mantamadiotis T., Lemberger T., Bleckmann S.C., Kern H., Kretz O., et al. Disruption of CREB function in brain leads to neurodegeneration. Nat. Genet. 31 (2002) 47-54
29. Menniti F.S., Faraci W.S., and Schmidt C.J. Phosphodiesterases in the CNS, targets for drug development. Nat. Rev. Drug Discov. 5 (2006) 660-670
30. Menniti F.S., Chappie T.A., Humphrey J.M., and Schmidt C.J. Phosphodiesterase 10A inhibitors, a novel approach to the treatment of the symptoms of schizophrenia. Curr. Opin. Investig. Drugs 8 (2007) 54-59
31. Nakano K., Kayahara T., Tsutsumi T., and Ushiro H. Neural circuits and functional organization of the striatum. J. Neurol. 247 Suppl. 5 (2000) V1-15
32. Nucifora Jr. F.C., Sasaki M., Peters M.F., Huang H., Cooper J.K., et al. Interference by huntingtin and atrophin-1 with cbp-mediated transcription leading to cellular toxicity. Science 291 (2001) 2423-2428
33. Sano H., Nagai Y., Myyakawa T., Shigemoto R., and Yokoi M. Increased social interaction in mice deficient of the striatal medium spiny neuron specific phosphodiesterase 10A2. J. Neurochem. 105 2 (2008) 546-556
34. Schmidt C.J., Chapin D.S., Cianfrogna J., Corman M.L., Hajos M., et al. Preclinical characterization of selective phosphodiesterase 10A inhibitors, a new therapeutic approach to the treatment of schizophrenia. J. Pharmacol. Exp. Ther. 325 (2008) 681-690
35. Seeger T.F., Bartlett B., Coskran T.M., Culp J.S., James L.C., et al. Immunohistochemical localization of PDE10A in the rat brain. Brain Res. 985 (2003) 113-126
36. Shimohata T., Onodera O., and Tsuji S. Interaction of expanded polyglutamine stretches with nuclear transcription factors leads to aberrant transcriptional regulation in polyglutamine diseases. Neuropathology 20 (2000) 326-333
37. Siuciak J.A., Chapin D.S., Harms J.F., Lebel L.A., McCarthy S.A., et al. Inhibition of the striatum-enriched phosphodiesterase PDE10A, a novel approach to the treatment of psychosis. Neuropharmacology 51 (2006) 386-396
38. Siuciak J.A., McCarthy S.A., Chapin D.S., Fujiwara R.A., James L.C., et al. Genetic deletion of the striatum-enriched phosphodiesterase PDE10A, evidence for altered striatal function. Neuropharmacology 51 (2006) 374-385
39. Steffan J.S., Kazantsev A., Spasic-Boskovic O., Greenwald M., Zhu Y.Z., et al. The Huntington's disease protein interacts with p53 and CREB-binding protein and represses transcription. Proc. Natl. Acad. Sci. U. S. A. 97 (2000) 6763-6768
40. Steffan J.S., Bodai L., Pallos J., Poelman M., McCampbell A., et al. Histone deacetylase inhibitors arrest polyglutamine-dependent neurodegeneration in Drosophila. Nature 413 (2001) 739-743
41. Sugars K.L., and Rubinsztein D.C. Transcriptional abnormalities in Huntington disease. Trends Genet. 19 (2003) 233-238
42. Sugars K.L., Brown R., Cook L.J., Swartz J., and Rubinsztein D.C. Decreased cAMP response element-mediated transcription, an early event in exon 1 and full-length cell models of Huntington's disease that contributes to polyglutamine pathogenesis. J. Biol. Chem. 279 (2004) 4988-4999
43. The Huntington's Disease Collaborative Research Group. A novel gene containing a trinucleotide repeat is expanded and unstable on Huntington's disease chromosomes. Cell 72 (1993) 971-983
44. Vonsattel J.P., and DiFiglia M. Huntington disease. J. Neuropathol. Exp. Neurol. 57 (1998) 369-384
45. Vonsattel J.P., Myers R.H., Stevens T.J., Ferrante R.J., Bird E.D., et al. Neuropathological classification of Huntington's disease. J. Neuropathol. Exp. Neurol. 44 (1985) 559-577
46. Walton M., Sirimanne E., Williams C., Gluckman P., and Dragunow M. The role of the cyclic AMP-responsive element binding protein CREB. in hypoxic-ischemic brain damage and repair. Brain Res. Mol. Brain Res. 43 (1996) 21-29
47. Walton M., Woodgate A.M., Muravlev A., Xu R., During M.J., et al. CREB phosphorylation promotes nerve cell survival. J. Neurochem. 73 (1999) 1836-1842
48. Wilson R.S., Como P.G., Garron D.C., Klawans H.L., Barr A., et al. Memory failure in Huntington's disease. J. Clin. Exp. Neuropsychol. 9 (1987) 147-154
49. Wyttenbach A., Swartz J., Kita H., Thykjaer T., Carmichael J., et al. Polyglutamine expansions cause decreased CRE-mediated transcription and early gene expression changes prior to cell death in an inducible cell model of Huntington's disease. Hum. Mol. Genet. 10 (2001) 1829-1845
50. Xie Z., Adamowicz W.O., Eldred W.D., Jakowski A.B., Kleiman R.J., et al. Cellular and subcellular localization of PDE10A, a striatum-enriched phosphodiesterase. Neuroscience 139 (2006) 597-607
51. Zuccato C., and Cattaneo E. Role of brain-derived neurotrophic factor in Huntington's disease. Prog. Neurobiol. 81 (2007) 294-330
52. Zuccato C., Ciammola A., Rigamonti D., Leavitt B.R., Goffredo D., Conti L., MacDonald M.E., Friedlander R.M., Silani V., Hayden M.R., Timmusk T., Sipione S., and Cattaneo E. Loss of huntingtin-mediated BDNF gene transcription in Huntington's disease. Science. 293 5529 (2001) 493-498 (Jul 20; Epub 2001 Jun 14)